Alto Neuroscience, Inc. (ANRO)

NYSE: ANRO · IEX Real-Time Price · USD
15.05
+0.06 (0.40%)
Jul 22, 2024, 2:18 PM EDT - Market open
0.40%
Market Cap 407.83M
Revenue (ttm) n/a
Net Income (ttm) -42.44M
Shares Out 26.88M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 34,262
Open 15.00
Previous Close 14.99
Day's Range 14.34 - 15.44
52-Week Range 9.40 - 24.00
Beta n/a
Analysts Strong Buy
Price Target 35.00 (+132.56%)
Earnings Date Aug 2, 2024

About ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 2, 2024
Employees 67
Stock Exchange NYSE
Ticker Symbol ANRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price forecast is $35.0, which is an increase of 132.56% from the latest price.

Price Target
$35.0
(132.56% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsych...

6 days ago - Business Wire

Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of A...

4 weeks ago - Business Wire

Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Aw...

4 weeks ago - Business Wire

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place J...

7 weeks ago - Business Wire

Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as...

2 months ago - Business Wire

Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress...

2 months ago - Business Wire

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced upcoming data presentations that highlight the company's precision psychiatry pipeline and biomarker-b...

2 months ago - Business Wire

Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in devel...

3 months ago - Business Wire

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacod...

3 months ago - Business Wire

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress....

4 months ago - Business Wire

Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is ...

4 months ago - Business Wire

Alto Neuroscience to Participate in Upcoming Investor Conferences

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences: Jefferies Bio...

4 months ago - Business Wire

Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at ...

5 months ago - Business Wire

Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the closing of its previously announced upsized initial public offering of 9,246,000 shares of common ...

5 months ago - Business Wire

Alto Neuroscience (ANRO) CEO On IPO & Treating Mental Health

Alto Neuroscience (ANRO) went public on the NYSE today. CEO Amit Etkin joins Nicole Petallides to give an overview of the company.

6 months ago - Schwab Network

Alto Neuroscience Announces Pricing of Upsized Initial Public Offering

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public off...

6 months ago - Business Wire

CNS disorder biotech Alto Neuroscience files for a $100 million IPO

Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

6 months ago - Renaissance Capital

Alto Neuroscience IPO Registration Document (S-1)

Alto Neuroscience has filed to go public with an IPO on the New York Stock Exchange (NYSE)

6 months ago - SEC